A Prospective Randomized Controlled Study of Immune Checkpoint Maintenance Therapy After Radiotherapy and Chemotherapy for Locally Advanced Head and Neck Tumors Based on Peripheral Blood CD8Tex Detection in Peripheral Blood

PHASE2RecruitingINTERVENTIONAL

Enrollment

104

Participants

Timeline

Start Date

January 25, 2024

Primary Completion Date

January 25, 2025

Study Completion Date

January 5, 2027

Conditions

Locally Advanced Head and Neck Squamous Cell Carcinoma

Interventions

DRUG

Sintilimab

Sintilimab is administered intravenously on the first day of each cycle. 21 days per cycle.

DRUG

Placebo

Placebo is administered intravenously on the first day of each cycle. 21 days per cycle.

Trial Locations (1)

RECRUITING

The Second Affiliated Hospital of Zhejiang University, Hangzhou

All Listed Sponsors

lead

Second Affiliated Hospital, School of Medicine, Zhejiang University

OTHER